3,450 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Acquired by Whipplewood Advisors LLC

Whipplewood Advisors LLC purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 3,450 shares of the company’s stock, valued at approximately $40,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Intellia Therapeutics by 27.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after acquiring an additional 794 shares during the period. Capstone Investment Advisors LLC increased its holdings in Intellia Therapeutics by 1.4% in the 3rd quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock valued at $1,256,000 after purchasing an additional 831 shares in the last quarter. KBC Group NV raised its position in Intellia Therapeutics by 37.3% in the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after purchasing an additional 1,020 shares during the period. Axxcess Wealth Management LLC lifted its stake in shares of Intellia Therapeutics by 5.4% during the third quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company’s stock worth $415,000 after purchasing an additional 1,044 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in shares of Intellia Therapeutics by 10.3% in the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock worth $320,000 after buying an additional 1,538 shares during the period. 88.77% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 29,000 shares of company stock valued at $352,551 over the last three months. Company insiders own 3.20% of the company’s stock.

Wall Street Analyst Weigh In

NTLA has been the topic of several analyst reports. Canaccord Genuity Group reiterated a “buy” rating and set a $90.00 target price on shares of Intellia Therapeutics in a report on Tuesday, November 19th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday. Morgan Stanley downgraded shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $56.00 to $11.00 in a research note on Monday, January 27th. Barclays dropped their price target on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, The Goldman Sachs Group reissued a “sell” rating and issued a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.12.

Intellia Therapeutics Trading Down 7.1 %

Shares of NASDAQ NTLA opened at $10.09 on Friday. Intellia Therapeutics, Inc. has a 12-month low of $8.96 and a 12-month high of $34.87. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -1.85 and a beta of 1.80. The stock’s 50 day simple moving average is $10.85 and its 200 day simple moving average is $15.64.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.